No connection

Search Results

BNGO vs GDTC

BNGO
Bionano Genomics, Inc.
BEARISH
Price
$1.15
Market Cap
$11.7M
Sector
Healthcare
AI Confidence
85%
GDTC
CytoMed Therapeutics Limited
BEARISH
Price
$1.00
Market Cap
$11.8M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
BNGO
--
GDTC
--
Forward P/E
BNGO
-0.46
GDTC
-6.67
P/B Ratio
BNGO
0.22
GDTC
2.31
P/S Ratio
BNGO
0.39
GDTC
13.74
EV/EBITDA
BNGO
-0.45
GDTC
-2.73

Profitability

Gross Margin
BNGO
45.97%
GDTC
89.57%
Operating Margin
BNGO
-115.89%
GDTC
-535.25%
Profit Margin
BNGO
-134.36%
GDTC
0.0%
ROE
BNGO
-78.22%
GDTC
-50.28%
ROA
BNGO
-19.31%
GDTC
-29.31%

Growth

Revenue Growth
BNGO
21.3%
GDTC
46.9%
Earnings Growth
BNGO
--
GDTC
--

Financial Health

Debt/Equity
BNGO
0.35
GDTC
0.07
Current Ratio
BNGO
2.12
GDTC
5.17
Quick Ratio
BNGO
1.14
GDTC
3.14

Dividends

Dividend Yield
BNGO
--
GDTC
--
Payout Ratio
BNGO
0.0%
GDTC
0.0%

AI Verdict

BNGO BEARISH

BNGO exhibits severe financial distress despite modest revenue growth, as reflected in its Piotroski F-Score of 1/9—indicating weak operational and financial health. The absence of an Altman Z-Score and the company's negative profitability metrics (e.g., -134.36% profit margin, -78.22% ROE) signal deep operational inefficiencies and high risk of insolvency. Although the stock shows a recent technical uptick and strong earnings surprise history, these are overshadowed by deteriorating fundamentals, massive losses, and a 5-year price decline of 100%. The lack of a Graham Number and intrinsic value estimate further underscores the absence of a reliable valuation anchor. Analysts have a target price of $5.50, but this is not supported by current fundamentals and appears speculative.

Strengths
21.30% year-over-year revenue growth indicates market traction in a high-growth sector
Gross margin of 45.97% suggests strong pricing power and cost control in product delivery
Recent quarterly earnings surprises (average +42.66%) show potential for better-than-expected execution
Risks
Piotroski F-Score of 1/9 is critically low, signaling severe financial deterioration and poor operational efficiency
Negative ROE (-78.22%) and ROA (-19.31%) reflect deep capital inefficiency and sustained losses
Profit margin of -134.36% and operating margin of -115.89% indicate unsustainable business model at current scale
GDTC BEARISH

GDTC exhibits a fragile financial profile characterized by a Piotroski F-Score of 4/9, placing it in the 'stable' but lower-tier health category. While the company maintains strong liquidity (Current Ratio 5.17) and very low debt, these are overshadowed by a catastrophic operating margin of -535.25% and a total lack of profitability. The technical trend is severely bearish (0/100), with the stock price having declined over 63% in the last year and 75% over five years. Despite positive revenue growth, the valuation remains disconnected from fundamentals, trading at a high Price/Sales ratio of 13.74 without a path to earnings.

Strengths
Strong liquidity position with a Current Ratio of 5.17
Very low leverage (Debt/Equity of 0.07)
High Gross Margin (89.57%) typical of high-potential biotech
Risks
Extreme operational inefficiency with an operating margin of -535.25%
Severe multi-year price erosion (-75% over 3-5 years)
Micro-cap volatility and lack of institutional analyst coverage

Compare Another Pair

BNGO vs GDTC: Head-to-Head Comparison

This page compares Bionano Genomics, Inc. (BNGO) and CytoMed Therapeutics Limited (GDTC) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile